Trending NewsTrending NewsNASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis $21.17 +0.51 (+2.47%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$21.08 -0.10 (-0.45%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arcutis Biotherapeutics Stock (NASDAQ:ARQT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ARQT alerts:Sign Up Key Stats Today's Range$20.25▼$21.3650-Day Range$20.66▼$28.5752-Week Range$12.72▼$31.77Volume2.71 million shsAverage Volume1.33 million shsMarket Capitalization$2.65 billionP/E RatioN/ADividend YieldN/APrice Target$34.00Consensus RatingModerate Buy Company Overview Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options. In August 2022, Arcutis received U.S. Food and Drug Administration approval for ZORYVE™ (roflumilast) cream, the company’s first commercial product, indicated for the treatment of plaque psoriasis in adults. Arcutis is also advancing a pipeline of next-generation roflumilast formulations, including topical ointments and foams, for the treatment of atopic dermatitis and seborrheic dermatitis. Additional clinical-stage programs include selective kinase inhibitors and other small-molecule assets aimed at expanding the company’s portfolio of dermatology therapies. Founded in 2017 and headquartered in Westlake Village, California, Arcutis has built a U.S. specialty commercial infrastructure to support the launch and market adoption of its products. The company is led by President and Chief Executive Officer Steven L. Gothel, whose leadership team brings extensive experience in dermatology drug development, regulatory affairs and commercial operations. Arcutis continues to collaborate with academic investigators and patient advocacy groups to advance its clinical programs and address unmet needs in dermatology.AI Generated. May Contain Errors. Read More Arcutis Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreARQT MarketRank™: Arcutis Biotherapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 267th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingArcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialArcutis Biotherapeutics has a consensus price target of $34.00, representing about 60.6% upside from its current price of $21.17.Amount of Analyst CoverageArcutis Biotherapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arcutis Biotherapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth533.33% Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow by 533.33% in the coming year, from $0.15 to $0.95 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is -705.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is -705.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 13.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.76% of the float of Arcutis Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 15.62, which indicates bearish sentiment.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently decreased by 1.30%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.21 News SentimentArcutis Biotherapeutics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 40 news articles for Arcutis Biotherapeutics this week, compared to 7 articles on an average week.MarketBeat FollowsOnly 3 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,295,499.00 in company stock.Percentage Held by Insiders9.40% of the stock of Arcutis Biotherapeutics is held by insiders.Percentage Held by InstitutionsArcutis Biotherapeutics has minimal institutional ownership at this time.Read more about Arcutis Biotherapeutics' insider trading history. Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARQT Stock News HeadlinesArcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE ExpansionMay 9 at 9:58 AM | finance.yahoo.comArcutis Biotherapeutics (NASDAQ:ARQT) Earns "Buy" Rating from Needham & Company LLCMay 9 at 4:11 AM | americanbankingnews.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.May 10 at 1:00 AM | Paradigm Press (Ad)Arcutis Biotherapeutics (NASDAQ:ARQT) Lowered to Hold Rating by Wall Street ZenMay 9 at 1:10 AM | americanbankingnews.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8 at 4:00 PM | globenewswire.comAnalysts Conflicted on These Healthcare Names: Quanterix (QTRX) and Arcutis Biotherapeutics (ARQT)May 8 at 2:28 PM | theglobeandmail.comArcutis Biotherapeutics (NASDAQ:ARQT) Insider Patrick Burnett Sells 684 SharesMay 7 at 8:50 AM | insidertrades.comHoward Welgus Sells 7,144 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) StockMay 6, 2026 | insidertrades.comSee More Headlines ARQT Stock Analysis - Frequently Asked Questions How have ARQT shares performed this year? Arcutis Biotherapeutics' stock was trading at $29.04 at the beginning of the year. Since then, ARQT shares have decreased by 27.1% and is now trading at $21.17. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) released its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.07. The business had revenue of $105.40 million for the quarter, compared to the consensus estimate of $103.68 million. Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative trailing twelve-month return on equity of 1.41%. Read the conference call transcript. When did Arcutis Biotherapeutics IPO? Arcutis Biotherapeutics (ARQT) raised $150 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 9,375,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager. Who are Arcutis Biotherapeutics' major shareholders? Arcutis Biotherapeutics' top institutional shareholders include Jennison Associates LLC (3.98%), Candriam S.C.A. (0.87%), Fishman Jay A Ltd. MI (0.45%) and Peregrine Capital Management LLC (0.24%). Insiders that own company stock include Life Sciences Viii L Frazier, Todd Franklin Watanabe, Todd Watanabe, Larry Todd Edwards, David Joseph Topper, Masaru Matsuda, Patrick Burnett, Latha Vairavan, Howard G Welgus, Patrick J Heron, Sue-Jean Lin, Halley E Gilbert, Neha Krishnamohan and Terrie Curran. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcutis Biotherapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA), Meta Platforms (META) and SPDR Dow Jones Industrial Average ETF Trust (DIA). Company Calendar Last Earnings5/06/2026Today5/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (20m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ARQT's financial health is in the Green zone, according to TradeSmith. ARQT has been in this zone for over 20 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARQT CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees150Year Founded2016Price Target and Rating Average Price Target for Arcutis Biotherapeutics$34.00 High Price Target$36.00 Low Price Target$29.00 Potential Upside/Downside+60.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.03) Trailing P/E RatioN/A Forward P/E Ratio141.13 P/E GrowthN/ANet Income-$16.14 million Net Margins-0.57% Pretax Margin-0.33% Return on Equity-1.41% Return on Assets-0.59% Debt Debt-to-Equity Ratio0.54 Current Ratio2.68 Quick Ratio2.99 Sales & Book Value Annual Sales$376.07 million Price / Sales7.04 Cash FlowN/A Price / Cash FlowN/A Book Value$1.52 per share Price / Book13.93Miscellaneous Outstanding Shares125,080,000Free Float113,325,000Market Cap$2.65 billion OptionableOptionable Beta1.58 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ARQT) was last updated on 5/10/2026 by MarketBeat.com Staff. From Our PartnersMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredTrump Just Named His Secret AI Project. It's Called "Golden Dawn."Behind a hidden government lab in Tennessee, 40,000 scientists are reportedly finishing work on an AI system d...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
